fbpx
Medical Innovation Exchange

After deeming success unlikely, Merck KGaA cuts lung cancer trial to consider future of ATR inhibitor

https://www.fiercebiotech.com/biotech/after-deeming-success-unlikely-merck-kgaa-cuts-lung-cancer-trial-consider-future-atr

Leave a Comment

Your email address will not be published.

Leave the field below empty!

This site uses Akismet to reduce spam. Learn how your comment data is processed.